Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
Hôpital Universitaire de Mirebalais, Mirebalais, Haiti.
Oncologist. 2020 Sep;25(9):e1372-e1381. doi: 10.1634/theoncologist.2019-0951. Epub 2020 Jul 13.
There are few studies on breast cancer outcomes in the Caribbean region. This study identified a retrospective cohort of female patients with nonmetastatic breast cancer in Haiti and conducted survival analyses to identify prognostic factors that may affect patient outcomes.
The cohort included 341 patients presenting between June 2012 and December 2016. The primary endpoint was event-free survival (EFS), defined as time to disease progression, recurrence, or death. Descriptive summaries of patient characteristics and treatments were reported. Survival curves were plotted using Kaplan-Meier estimation. Multivariate survival analyses were performed using Cox proportional hazards regression.
Median age at diagnosis was 49 years, with 64.2% being premenopausal. Most patients (55.1%) were staged as locally advanced. One hundred and sixty patients received neoadjuvant therapy: 33.3% of patients with early stage disease and 61.2% of those with locally advanced stage disease. Curative-intent surgery was performed in 278 (81.5%) patients, and 225 patients received adjuvant therapy. Adjuvant endocrine therapy was used in 82.0% of patients with estrogen receptor-positive disease. During the follow-up period, 28 patients died, 77 had disease recurrence, and 10 had progressive disease. EFS rates at 2 years and 3 years were 80.9% and 63.4%, respectively. After controlling for multiple confounders, the locally advanced stage group had a statistically significant adjusted hazard ratio for EFS of 3.27 compared with early stage.
Patients with nonmetastatic breast cancer in Haiti have more advanced disease, poorer prognostic factors, and worse outcomes compared with patients in high-income countries. Despite several limitations, curative treatment is possible in Haiti.
Patients with breast cancer in Haiti have poor outcomes. Prior studies show that most Haitian patients are diagnosed at later stages. However, there are no rigorous studies describing how late-stage diagnosis and other prognostic factors affect outcomes in this population. This study presents a detailed analysis of survival outcomes and assessment of prognostic factors in patients with nonmetastatic breast cancer treated in Haiti. In addition to late-stage diagnosis, other unfavorable prognostic factors identified were young age and estrogen receptor-negative disease. The study also highlights that the availability of basic breast cancer treatment in Haiti can lead to promising early patient outcomes.
加勒比地区关于乳腺癌结局的研究较少。本研究确定了海地非转移性乳腺癌女性患者的回顾性队列,并进行了生存分析,以确定可能影响患者结局的预后因素。
该队列纳入了 2012 年 6 月至 2016 年 12 月期间就诊的 341 例患者。主要终点为无事件生存(EFS),定义为疾病进展、复发或死亡的时间。报告了患者特征和治疗的描述性总结。使用 Kaplan-Meier 估计绘制生存曲线。使用 Cox 比例风险回归进行多变量生存分析。
中位诊断年龄为 49 岁,64.2%为绝经前。大多数患者(55.1%)分期为局部晚期。160 例患者接受了新辅助治疗:33.3%的早期疾病患者和 61.2%的局部晚期疾病患者。278 例(81.5%)患者接受了根治性手术,225 例患者接受了辅助治疗。雌激素受体阳性疾病患者中 82.0%接受了辅助内分泌治疗。在随访期间,28 例患者死亡,77 例患者疾病复发,10 例患者疾病进展。2 年和 3 年 EFS 率分别为 80.9%和 63.4%。在控制了多个混杂因素后,局部晚期组的 EFS 调整后风险比具有统计学意义,为 3.27 与早期组相比。
海地非转移性乳腺癌患者的疾病更晚期,预后因素更差,结局更差,与高收入国家的患者相比。尽管存在一些局限性,但在海地仍有可能进行根治性治疗。
海地乳腺癌患者的结局较差。既往研究表明,大多数海地患者的诊断分期较晚。然而,尚无严格的研究描述晚期诊断和其他预后因素如何影响该人群的结局。本研究详细分析了在海地接受治疗的非转移性乳腺癌患者的生存结局和预后因素评估。除了晚期诊断外,确定的其他不良预后因素还包括年轻和雌激素受体阴性疾病。该研究还强调,海地基本乳腺癌治疗的提供可以带来早期患者良好的结局。